Suggested Reading

Abe S, Oda I, Inaba K, et al: A retrospective study of 5-year outcomes of radiotherapy for gastric mucosa-associated lymphoid tissue lymphoma refractory to Helicobacter pylori eradication therapy. Jpn J Clin Oncol 43:917–922, 2013.

Barta SK, Xue X, Wang D, et al: Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients. Blood 122:3251–3262, 2013.

Bödör C, Grossmann V, Popov N, et al: EZH2 mutations are frequent and represent an early event in follicular lymphoma. Blood 122:3165–3168, 2013.

Cerhan JR, Berndt SI, Vijai J, et al: Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. Nat Genet 46:1233–1238, 2014.

Cheson BD, Pfistner B, Juweid ME, et al: Revised response criteria for malignant lymphoma. J Clin Oncol 25:579–586, 2007.

Coutinho R, Clear AJ, Owen A, et al: Poor concordance among nine immunohistochemistry classifiers of cell-of-origin for diffuse large B-cell lymphoma: Implications for therapeutic strategies. Clin Cancer Res 19:6686–6695, 2013.

Delabie J, Holte H, Vose JM, et al: Enteropathy-associated T-cell lymphoma: Clinical and histological findings from the International Peripheral T-Cell Lymphoma Project. Blood 118:148–155, 2011.

de Masson A, Beylot-Barry M, Bouaziz JD, et al: Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous Lymphomas. Haematologica 99:527–534, 2014.

Dunleavy K, Pittaluga S, Maeda LS, et al: Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med 368:1408–1416, 2013.

Dunleavy K, Pittaluga S, Shovlin M, et al: Low-intensity therapy in adults with Burkitt’s lymphoma. N Engl J Med 369:1915–1925, 2013.

Evens AM, Advani R, Press OW, et al: Lymphoma occurring during pregnancy: Antenatal therapy, complications, and maternal survival in a multicenter analysis. J Clin Oncol 31:4132–4139, 2013.

Evens AM, David KA, Helenowski I, et al: Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: Outcomes and prognostic factors in the modern era. J Clin Oncol 28:1038–1046, 2010.

Federico M, Bellei M, Marcheselli L, et al: Follicular lymphoma international prognostic index 2: A new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 27:4555–4562, 2009.

Fenske TS, Zhang MJ, Carreras J, et al: Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality. J Clin Oncol 32:273–281, 2014.

Fernàndez V, Salamero O, Espinet B, et al: Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res 70:1408–1418, 2010.

Foss FM, Zinzani PL, Vose JM, et al: Peripheral T-cell lymphoma. Blood 117:6756–6767, 2011.

Furman RR, Sharman JP, Coutre SE, et al: Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 370:997–1007.

Gopal AK, Kahl BS, de Vos S, et al: PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 370:1008–1018, 2014.

Goy A, Sinha R, Williams ME, et al: Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: Phase II MCL-001 (EMERGE) study. J Clin Oncol 31:3688–3695, 2013.

Green TM, Young KH, Visco C, et al: Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 30:3460–3467, 2012.

Herrmann A, Hoster E, Zwingers T, et al: Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 27:511–518, 2009.

Heslop HE, Slobod KS, Pule MA, et al: Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 115:925–935, 2010.

Hu S, Xu-Monette ZY, Tzankov A, et al: MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood 121:4021–4031, 2013.

Illidge T, Specht L, Yahalom J, et al: Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys 89:49–58, 2014.

Jegalian AG, Eberle FC, Pack SD, et al: Follicular lymphoma in situ: Clinical implications and comparisons with partial involvement by follicular lymphoma. Blood 118:2976–2984, 2011.

Jacobson C, LaCasce A: How I treat Burkitt lymphoma in adults. Blood 124:2913–2920, 2014.

Johnson NA, Slack GW, Savage KJ, et al: Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 30:3452–3459, 2012.

Kahl BS, Hong F, Williams ME, et al: Results of Eastern Cooperative Oncology Group Protocol E4402 (RESORT): A randomized phase III study comparing two different rituximab dosing strategies for low tumor burden follicular lymphoma. In: Proceedings from 53rd American Society of Hematology Annual Meeting and Exposition; December 10-13, 2011; San Diego, CA. Abstract LBA-6.

Kchour G, Tarhini M, Kooshyar MM, et al: Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL). Blood 113:6528–6532, 2009.

Kluin-Nelemans HC, Hoster E, Hermine O, et al: Treatment of older patients with mantle-cell lymphoma. N Engl J Med 367:520–531, 2012.

Kyriakou C, Canals C, Finke J, et al: Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: A retrospective study from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol 27:3951–3958, 2009.

Ladetto M, Lobetti-Bodoni C, Mantoan B, et al: Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program. Blood 122:3759–3766, 2013.

Lenz G, Wright G, Dave SS, et al: Stromal gene signatures in large B-cell lymphomas. N Engl J Med 359:2313–2323, 2008.

Link BK, Maurer MJ, Nowakowski GS, et al: Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource. J Clin Oncol 31:3272–3278, 2013.

Martin PJ, Counts GW Jr, Appelbaum FR, et al: Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. J Clin Oncol 28:1011–1016, 2010.

Morin RD, Mungall K, Pleasance E, et al: Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing. Blood 122:1256-1265, 2013.

Morris PG, Correa DD, Yahalom J, et al: Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: Final results and long-term outcome. J Clin Oncol 31:3971–3979, 2013.

Mullighan CG: Genome sequencing of lymphoid malignancies. Blood 122:3899–3907, 2013.

O’Brien S, Furman RR, Coutre SE, et al: Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: An open-label multicentre, phase 1b/2 trial. Lancet Oncol 15:48–58, 2014.

Ott G, Rosenwald A, Campo E: Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification. Blood 122:3884–3891, 2013.

Pérez-Galán P, Dreyling M, Wiestner A: Mantle cell lymphoma: Biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood 117:26–38, 2011.

Perry AM, Warnke RA, Hu Q, et al: Indolent T-cell lymphoproliferative disease of the gastrointestinal tract. Blood 122:3599–3606, 2013.

Pettengell R, Schmitz N, Gisselbrecht C, et al: Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol 31:1624–1630, 2013.

Poulain S, Roumier C, Decambron A, et al: MYD88 L265P mutation in Waldenstrom macroglobulinemia. Blood 121:4504–4511, 2013.

Pugh TJ, Ballonoff A, Newman F, et al: Improved survival in patients with early stage low-grade follicular lymphoma treated with radiation. Cancer 116:3843–3851, 2010.

Rummel MJ, Niederle N, Maschmeyer G, et al: Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: An open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381:1203–1210, 2013.

Salles G, Seymour JF, Offner F, et al: Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomised controlled trial. Lancet 377:42–51, 2011.

Senff NJ, Noordijk EM, Kim YH, et al: European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood 112:1600–1609, 2008.

Shiels MS, Engels EA, Linet MS, et al: The epidemic of non-Hodgkin lymphoma in the United States: disentangling the effect of HIV, 1992-2009. Cancer Epidemiol Biomarkers Prev 22:1069–1078, 2013.

Shimada K, Matsue K, Yamamoto K, et al: Retrospective analysis of intravascular large B-cell lymphoma treated with rituximab-containing chemotherapy as reported by the IVL Study Group in Japan. J Clin Oncol 26:3189–3195, 2008.

Smith SM, Burns LJ, van Besien K, et al: Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. J Clin Oncol 31: 3100–3109, 2013.

Styczynski J, Gil L, Tridello G, et al: Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Clin Infect Dis 57: 794–802, 2013.

Suzumiya J, Ohshima K, Tamura K, et al: The International Prognostic Index predicts outcome in aggressive adult T-cell leukemia/lymphoma: Analysis of 126 patients from the International Peripheral T-Cell Lymphoma Project. Ann Oncol 20:715–721, 2009.

Tan D, Horning SJ, Hoppe RT, et al: Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: The Stanford University experience. Blood 122:981–987, 2013.

Trappe R, Oertel S, Leblond V; German PTLD Study Group, European PTLD Network: Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): The prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol 13:196–206, 2012.

Trautinger F, Knobler R, Willemze R, et al: EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. Eur J Cancer 42:1014–1030, 2006.

Treon SP, Xu L, Yang G, et al: MYD88 L265P somatic mutation in Waldenström’s macroglobulinemia. N Engl J Med 367:826–833, 2012.

Tsukasaki K, Hermine O, Bazarbachi A, et al: Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: A proposal from an international consensus meeting. J Clin Oncol 27:453–459, 2009.

Vegliante MC, Palomero J, Pérez-Galán P, et al: SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma. Blood 121:2175–2185, 2013.

Vitolo U, Chiappella A, Ferreri AJ, et al: First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: Final results of an international phase II trial. J Clin Oncol 29:2766–2772, 2011.

Wagner LI, Zhao F, Williams ME, et al: Quality of life results from Eastern Cooperative Oncology Group Protocol E4402 (RESORT): A randomized phase III study comparing two different rituximab dosing strategies for indolent non Hodgkin’s-lymphoma. In: Proceedings from 54th American Society of Hematology Annual Meeting and Exposition; December 8-11, 2012; Atlanta, GA. Abstract 235.

Wang M, Rule SA, Martin P, et al: Interim results of an international, multicenter, phase 2 study of Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765) in relapsed or refractory mantle cell lymphoma (MCL): Durable efficacy and tolerability with longer follow-up. Presented at: 54th ASH Annual Meeting and Exposition; December 8-11, 2012; Atlanta, GA. Abstract 904.

Wang ML, Rule S, Martin P, et al: Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 369:507–516, 2013.

Weisenburger DD, Savage KJ, Harris NL, et al: Peripheral T-cell lymphoma, not otherwise specified: A report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood 117:3402–3408, 2011.

Westin JR, Chu F, Zhang M, et al: Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol 15:69–77, 2014.

Willemze R, Jaffe ES, Burg G: WHO-EORTC classification for cutaneous lymphomas. Blood 105:3768–3785, 2005.

Williams ME, Hong F, Kahl BS, et al: A subgroup analysis of small lymphocytic and marginal zone lymphomas in the Eastern Cooperative Oncology Group protocol E4402 (RESORT): A randomized phase III study comparing two different rituximab dosing strategies for low tumor burden indolent non-Hodgkin lymphoma. J Clin Oncol 30:suppl; abstract 8007, 2012.

Younes A, Bartlett NL, Leonard JP, et al: Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363:1812–1821, 2010.

Zhou Z, Sehn LH, Rademaker AW, et al: An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood 123:837–842, 2014.